Skip to main content
MedPath Trial logoMedPath TrialMedPath Trial Home
Clinical Trials/NCT02869568
NCT02869568RecruitingNot Applicable

Institut Paoli Calmettes Ovarian Cancer Database

Institut Paoli-Calmettes1 site in 1 country6,000 target enrollmentStarted: January 2000Last updated:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
Conditions

Trial Snapshot

Phase
Not Applicable
Status
Recruiting
Sponsor
Enrollment
6,000
Locations
1
Primary Endpoint
Survival of patients
Study OverviewStudy DesignEligibility CriteriaOutcomesInvestigatorsSitesRecords & IdentifiersSimilar Trials

Study Overview

Brief Summary

Database of Institut Paoli-Calmettes patients diagnosed with ovarian cancer

Study Design

Study Type
Observational
Observational Model
Cohort
Time Perspective
Prospective

Eligibility Criteria

Ages
18 Years to 95 Years (Adult, Older Adult)
Sex
Female
Accepts Healthy Volunteers
No

Inclusion Criteria

  • •Patient with a diagnosis of ovarian cancer

Exclusion Criteria

  • •Diagnosis of fallopian tube cancer

Outcomes

Primary Outcomes

Survival of patients

Time Frame: 10 years

Overall survival of all patients who come in the center

Secondary Outcomes

  • Collection of patients characteristics(10 years)

Investigators

Sponsor
Institut Paoli-Calmettes
Sponsor Class
Other
Responsible Party
Sponsor

Study Sites (1)

Loading locations...

Similar Trials

Not yet recruiting
Not Applicable
DKI Combined With APT for Post-treatment Assessment of Ovarian Malignancies and Correlation With XRCC2 GeneMalignant Tumor of the OvaryXRCC2 Gene Mutation
NCT05642871Qianqian Qu2
Unknown
Not Applicable
Screening of Biomarkers on Endometrial CancersEndometrial Cancers
NCT00674349National Taiwan University Hospital250
Unknown
Not Applicable
Screening and Identification of Ovarian CancersOvarian Cancer
NCT00854399National Taiwan University Hospital250
Unknown
Phase 2
Efficacy and Safety of Paclitaxel (Albumin-bound) Combination With Carboplatin in Ovarian Cancer.Ovarian Cancer
NCT04661696Chinese Academy of Medical Sciences75
Completed
Not Applicable
Development and Validation of a Prediction Model for AKI Following Cisplatin-Based HIPEC in Patients With Ovarian CancerAKI - Acute Kidney InjuryOvarian Cancer
NCT06697613Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University150